Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/04/2003WO2003049786A3 Metering valve and pharmaceutical metered dose inhaler and methods thereof
12/04/2003WO2003049692A3 The use of acyl salicylates as heat shock inducers
12/04/2003WO2003045917B1 Ccr-3 receptor antagonists vii
12/04/2003WO2003045910A3 Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
12/04/2003WO2003043581A3 Composition and method for modulating bar/fxr receptor activity
12/04/2003WO2003041564A3 Method for effecting hemostasis
12/04/2003WO2003039540A3 D-amino acid oxidase inhibitors for learning and memory
12/04/2003WO2003039453A3 Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
12/04/2003WO2003030878A3 Galenic microparticulate oral formulation
12/04/2003WO2003030867A3 Method for preparing an interactive compound of an anilide derivative with a porous support by supercritical fluid
12/04/2003WO2003029417A3 Nutrient medium for maintaining neural cells in injured nervous system
12/04/2003WO2003028736A3 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised
12/04/2003WO2003028715A3 Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
12/04/2003WO2003028709A3 Use of mannosamine derivatives for the stimulation of neurite growth
12/04/2003WO2003028642A3 Methods of inhibiting metastases
12/04/2003WO2003028537A3 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
12/04/2003WO2003028001A3 Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol
12/04/2003WO2003027085A3 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
12/04/2003WO2003024405A3 Methods and compositions for inhibiting the proliferation of prostate cancer cells
12/04/2003WO2003022217A3 Treatment of excessive radiation (e.g. sunburn) exposure
12/04/2003WO2003020280A3 Compositions and use thereof in the treatment of cancer
12/04/2003WO2003018755A3 Wild-type ras as a cancer therapeutic agent
12/04/2003WO2003018568A3 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
12/04/2003WO2003018019A3 New use of cyclic compounds
12/04/2003WO2003017991A3 Injection solution containing a dihydropyridin derivative
12/04/2003WO2003017949A3 Novel synthetic ganglioside derivatives and compositions thereof
12/04/2003WO2003017941A3 Flexible applicator for applying oil-in-water emulsion with improved stability
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003014145A3 Peptides that bind to atherosclerotic lesions
12/04/2003WO2003013554A3 Aromatase inhibitors from broussonetia papyrifera
12/04/2003WO2003012043A3 Enhancing organ maturity in neonates and predicting their duration of intensive care
12/04/2003WO2003011264A3 Betacarboline derivatives as gaba a-receptor-modulators having nmda-antagonistic activity for treating diseases of the central nervous system
12/04/2003WO2003011225A3 Calcium glutarate supplement and phosphorus binder
12/04/2003WO2003010138A3 Piperidine derivatives as antibacterial agents
12/04/2003WO2003009704A3 Enteral compositions for the prevention and/or treatment of sepsis
12/04/2003WO2003007909A3 Cosmetic or dermatological preparations having a long-lasting cooling effect
12/04/2003WO2003005954B1 Methods and materials for the treatment of testosterone deficiency in men
12/04/2003WO2003003971A3 Use of antidiabetics for making a medicine with cicatrizing effect
12/04/2003WO2002098515A3 Topical treatments using alkanolamines
12/04/2003WO2002094186A3 Urazole compounds useful as anti-inflammatory agents
12/04/2003WO2002088069A9 Compounds useful as intermediates for 4-aminoquinoline derivatives
12/04/2003WO2002086090A3 Identification of essential genes of aspegillus fumigatus and methods of use
12/04/2003WO2002078747A8 Pregabalin lactose conjugates
12/04/2003WO2002074970A8 A process for the production of an inhibitor of human platelet aggregation and soybean lipoxygenase
12/04/2003WO2002074314A9 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
12/04/2003WO2002073208A3 Anti-epileptogenic agents
12/04/2003WO2002070708A3 Glutamate receptor modulatory proteins and nucleic acids encoding them
12/04/2003WO2002068635A3 Methods of inhibiting expression of a target gene in mammalian cells
12/04/2003WO2002068397A8 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
12/04/2003WO2002065977A3 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
12/04/2003WO2002058694A3 Method of treating hematologic tumors and cancers using beta lapachone
12/04/2003WO2002055080A3 Method of immunomodulation using thione-forming disulfides
12/04/2003WO2002049641A3 Anti-endoparasitic amidoacetonitrils
12/04/2003WO2002030462A3 Hedgehog antagonists, methods and uses related thereto
12/04/2003US20030226169 DNA sequences encoding antifungal proteins
12/04/2003US20030225460 Compositions for generating submucosal fluid cushions
12/04/2003US20030225450 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003US20030225300 Compounds and compositions for delivering active agents
12/04/2003US20030225287 Synthesis of chiral 2-alkyl amino acids
12/04/2003US20030225286 2-((3-Cyclohexyl-2-(2,5-dioxo-4-(thiophen-2-yl)methylimida-zol idin-1-yl)propanoyl)amino) thiazole-4-carboxylic acid methyl ester, e.g.; antidiabetic agents; hypoglycemic agents; a glucose sensor in beta-cells and hepatocytes
12/04/2003US20030225285 Oxidizing a protected aminoalcohol to a chiral protected aminoaldehyde and diastereoselectively forming the aminoepoxide from said aminoaldehyde with an organometallic methylene-adding reagent in an appropriate solvent
12/04/2003US20030225283 2-Substituted phenyl,3-polar ring,N-heroaromatic propion-amides, e.g., 1-(2-(3,4-Dichlorophenyl)-3-(tetrahydro-furan-2-yl)-propionyl)-3- methylurea; antidiabetic agents; increase the flux of glucose metabolism in beta-cells and hepatocytes
12/04/2003US20030225277 9-(2-(2,4-cis(S)-4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphor-inan-2 -yl)methoxyethyl)adenine by coupling the dichloridate of 9-(2-phosphonyl- methoxyethyl- or propyl)adenine (PMEA)(PMPA) with a 1-(chlorophenyl) propylene-1,3-diol
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225271 Compounds useful as reversible inhibitors of cysteine proteases
12/04/2003US20030225270 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis
12/04/2003US20030225269 Inhibitors of interleukin-1beta converting enzyme
12/04/2003US20030225266 N-aromatic or heteroaromatic-oxyalkylene, hydrocarbylnamide derivatives useful for potentiating glutamate receptor function; Alzheimer's Disease; antidepressants; cognition activators; psychosis; psychiatric and neurological disorders
12/04/2003US20030225252 PNA monomer and precursor
12/04/2003US20030225250 Intestinal trefoil proteins
12/04/2003US20030225164 Carbocyclic amines such as 4-(3-(4-Phenylcyclohexylamino)-propyl)phenol, administered as N-Methyl-D-Aspartate (NMDA) receptor inhibitors, for prophylaxis of cardiovascular, brain or nervous system disorders
12/04/2003US20030225163 Sulfonamide derivatives
12/04/2003US20030225162 Monitoring and evaluation, to reduce side effects such as metabolic, cardiovascular or muscular disorders, during prophylaxis of urogenital disorders, then admininstering carnitine isomers
12/04/2003US20030225161 GABA and L-glutamic acid analogs for antiseizure treatment
12/04/2003US20030225160 Esterified hydroxytyrosol; 2-(3,4-dihydroxyphenyl)ethyl acetate for example
12/04/2003US20030225159 By administering a glycol derivative, specifically diethylene glycol dibenzoate controlling replication of HIV by exposing an infected cell to said glycol derivative
12/04/2003US20030225158 Compounds that modulate PPAR activity and methods for their preparation
12/04/2003US20030225156 Which are not psychoactive; method of use treating chemotherapy-induced nausea
12/04/2003US20030225155 Treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, heavy metal poisoning and immunogical diseases with thiophene-2-carboxylic acid, 2-furoic acid or derivatives
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225150 Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
12/04/2003US20030225149 Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225146 Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds
12/04/2003US20030225144 Anticoagulants, methyl (2R,3R)-2-(3-(amino(imino)methyl)benzyl)-3-((4-(1-oxido-4-pyridinyl) benzoyl)amino)butanoate; therapeutic treatment of cardiovascular disorders
12/04/2003US20030225143 A nicotinate salt of amlodipine, used as hypotensive agents, antiischemic agents; stability, water solubility
12/04/2003US20030225141 Thiazole derivatives
12/04/2003US20030225140 Use of 2-amino-4-heteroarylethyl-thiazoline derivatives as inhibitors of inducible no-synthase
12/04/2003US20030225139 Administering to a mammal having a pituitary tumor an effective amount of a peroxisome proliferator activated receptor gamma ligand selected from rosiglitazone, pioglitazone, and troglitazone.
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225137 2-pyridinyl)-methyl)sulfinyl)-1H-benzimidazole derivatives
12/04/2003US20030225136 Heterocyclic imines such as (5)6-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H -benzimidazole and salts, used as antisecretory agents
12/04/2003US20030225135 Dry-blend pharmaceutical formulations
12/04/2003US20030225134 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance
12/04/2003US20030225132 Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders
12/04/2003US20030225131 Thrombin inhibitors
12/04/2003US20030225130 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
12/04/2003US20030225128 For treating conditions such as erectile dysfunction, cardiovascular disorders, male or female sexual dysfunction, diabetes mellitus, and gastrointestinal disorders
1 ... 5253 5254 5255 5256 5257 5258 5259 5260 5261 5262 5263 5264 5265 5266 5267 5268 5269 5270 5271 5272 5273 ... 7860